نتایج جستجو برای: sustained virology response svr

تعداد نتایج: 1047399  

2004

The current standard of treatment for hepatitis C virus (HCV) is a combination of two drugs: pegylated interferon and ribavirin. The virological response rate, treatment duration, and ribavirin dose vary according to several prognostic factors: genotype, baseline HCV RNA (viral load), race, body weight, age, and liver histology. In one study, 48 weeks of pegylated interferon plus ribavirin led ...

2011
Glenn Wagner Karen Chan Osilla Jeffrey Garnett Bonnie Ghosh-Dastidar Laveeza Bhatti Matthew Bidwell Goetz Mallory Witt

Background. Hepatitis C (HCV) treatment efficacy among HIV patients is limited by poor treatment adherence and tolerance, but few studies have examined the psychosocial determinants of treatment adherence and outcomes. Methods. Chart abstracted and survey data were collected on 72 HIV patients who had received pegylated interferon and ribavirin to assess correlates of treatment adherence, compl...

Journal: :Annals of hepatology 2012
Laura E Martínez-Gómez Norberto C Chávez-Tapia Ana I Burguete-García Nancy Aguilar-Olivos Vicente Madrid-Marina Margarita Román-Bahena Citlalli Orbe-Orihuela Uribe Misael Nahum Méndez-Sánchez

INTRODUCTION The treatment of hepatitis C virus (HCV) genotype 1 with ribavirin (RBV) and pegylated-interferon alpha (peg-IFNα) provides a low-level sustained virological response (SVR). Single nucleotide polymorphisms (SNPs) in the interleukin 28B (IL28B) gene have been identified as SVR predictors. Our aim was to establish an association between three IL28B SNPs (rs8099917, rs12979860, and rs...

Journal: :Drug and alcohol dependence 2015
Heather Valerio David J Goldberg James Lewsey Amanda Weir Samuel Allen Esther J Aspinall Stephen T Barclay Peter Bramley John F Dillon Ray Fox Andrew Fraser Peter C Hayes Hamish Innes Nicholas Kennedy Peter R Mills Adrian J Stanley Sharon J Hutchinson

BACKGROUND People who inject drugs (PWID) are at the greatest risk of hepatitis C virus (HCV) infection, yet are often denied immediate treatment due to fears of on-going risk behaviour. Our principal objective was to examine evidence of continued injecting drug use among PWID following successful treatment for HCV and attainment of a sustained viral response (SVR). METHODS PWID who attained ...

Journal: :Hepatology 2009
Rami Moucari Vincent Mackiewicz Olivier Lada Marie-Pierre Ripault Corinne Castelnau Michelle Martinot-Peignoux Agnes Dauvergne Tarik Asselah Nathalie Boyer Pierre Bedossa Dominique Valla Michel Vidaud Marie-Hélène Nicolas-Chanoine Patrick Marcellin

UNLABELLED Pegylated interferon alfa-2a (PEG-IFN) may induce sustained virological response (SVR) in 20% of hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. In addition, loss of hepatitis B surface antigen (HBsAg) is achieved with a 10% yearly rate after treatment cessation in sustained responders. The aim of this study was to assess on-treatment serum HBsAg kinetics t...

2012
Hamad I. Al-Ashgar Mohammed Q. Khan Abdulrahman Aljumah Faisal M. Sanai Ayman A. Abdo Mutasim M. Dafalla Mosa A. Fagih Khalid I. Bzeizi

BACKGROUND Peginterferon (PEG-IFN) α-2a has been shown to induce a sustained virologic response (SVR) in 20-30% of "hepatitis B e antigen (HBeAg)"-negative patients. AIM To determine the safety and efficacy of PEG-IFN α-2a in HBeAg-negative, genotype D-naive patients and to analyze the predictors of response. METHODS This prospective, multicenter, open-label, nonrandomized trial was conduct...

2009
Tsuyoshi Mashitani Hitoshi Yoshiji Masaharu Yamazaki Yasuhide Ikenaka Ryuichi Noguchi Masatoshi Ishikawa Hideto Kawaratani Norihide Matsuo Masahito Uemura Junichi Yamao Masao Fujimoto Akira Mitoro Masahisa Toyohara Motoyuki Yoshida Masayoshi Sawai Chie Morioka Tatsuhiro Tsujimoto Mitsuteru Kitade Kosuke Kaji Yosuke Aihara Hiroshi Fukui

BACKGROUND Although several recent reports have shown that hepatocellular carcinoma (HCC) developed in patients with chronic hepatitis C (CH-C) even after having a sustained virological response (SVR) to interferon (IFN) therapy, it is not common for HCC to develop more than 10 years after SVR. CASE PRESENTATION A 73-year-old Japanese man with CH-C who achieved SVR to IFN therapy 13 years ago...

2012
Adriano M Pellicelli Mario Romano Tommaso Stroffolini Ettore Mazzoni Fabrizio Mecenate Roberto Monarca Antonio Picardi Maria Elena Bonaventura Cristina Mastropietro Pascal Vignally Arnaldo Andreoli Massimo Marignani Cecilia D’Ambrosio Lucia Miglioresi Lorenzo Nosotti Olga Mitidieri Umberto Vespasiani Gentilucci Claudio Puoti Giuseppe Barbaro Angelo Barlattani Caterina Furlan Giorgio Barbarini

BACKGROUND The impact of viral subtype on the rate of sustained virological response (SVR) to antiviral therapy in patients chronically infected with hepatitis C genotype 1 subtype 1a and 1b has not been extensively investigated. The aim of this study is to determine whether the HCV genotype 1 subtypes 1a and 1b respond differently to treatment with PEGylated interferon (PEG-IFN) plus ribavirin...

2010
Dimitrios Dimitroulopoulos Ioannis Elefsiniotis Christos Pavlidis Dimitrios Xinopoulos Klisthenis Tsamakidis Stamatina Patsavela Dimitrios Kypreos Ageliki Ferderigou Dimitrios Korkolis Sotirios Koutsounas Georgios Saroglou Emmanouil Paraskevas

BACKGROUND AND AIMS Despite the recent spread of hepatitis C virus genotype 4 (HCV-4) into European countries, very little is known about the influence of ethnicity on treatment outcomes in patients with HCV-4. The aim of this study was to compare the virologic response (VR) rates of: rapid virologic response (RVR), early virologic response (EVR), VR at 24 weeks of treatment, at end of treatmen...

2017
Su Rin Shin Young Seok Kim Young-Seok Lim June Sung Lee Jin Woo Lee Sun Myung Kim Sook-Hyang Jeong Joo Hyun Sohn Myung Seok Lee Sang Hoon Park

Background/Aims Because of the limited geographic distribution, there have been insufficient data regarding hepatitis C virus (HCV) genotype 6 in Korea. This study aimed to investigate the clinical characteristics and available treatment outcomes of patients with genotype 6 HCV in Korea. Methods From 2004 to 2014, data were collected from Korean patients infected with genotype 6 HCV in eight ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید